title: Medication use and disease control of asthmatic patients in Flanders: a cross-sectional community pharmacy study.
abstract: The aim of this study was to describe medication use and disease management of asthmatic patients and to evaluate the usefulness of the Asthma Control Test (ACT) in community pharmacies. In 54 Flemish community pharmacies 166 asthmatic patients were included in the study. At inclusion, the study persons completed a survey to assess subject characteristics, symptoms and asthma attacks, and peak expiratory flow (PEF) was measured. Furthermore, the actual level of asthma control was assessed by ACT, a clinically validated measure of asthma control. Prescribed medicine data of the patients were 1 year retrospectively analysed from the prescriptions. Mean age of the sample was 36.8 year, 23% were smokers. As maintenance treatment, 63% of the patients used a combination product containing an inhaled corticosteroid and a long-acting beta2-agonist in a single inhaler. According to ACT, 49.1% of the patients were insufficiently controlled. Only 4.9% of the patients had a maximal ACT score of 25, indicating complete asthma control; 46.0% of the study population obtained an ACT score between 20 and 24, meaning that their asthma is well controlled. In contrast, 30.7% of the patients had a score between 15 and 19, indicating uncontrolled asthma. In all, 18.4% obtained ACT scores of less than 15, meaning that their asthma was seriously out of control and necessitating referral to their general practitioner or lung specialist. Importantly, the correlation between the self-perceived level of asthma control and the objective assessment of the asthma control level was poor: 82.3% of the patients believed their asthma to be totally or well controlled, while this was the fact for only 50.9% of the patients. In conclusion, the ACT appears to be a useful tool to determine rapidly and accurately the level of asthma control in patients presenting at community pharmacies.
authors.affiliation: Pharmaceutical Care Unit Ghent, Faculty of Pharmaceutical Sciences, Ghent University, Department of Respiratory Diseases, Ghent University Hospital, Harelbekestraat 72, 9000 Ghent, Belgium. els.mehuys@ugent.be
authors.forename: E
authors.initials: E
authors.lastname: Mehuys
authors.forename: L
authors.initials: L
authors.lastname: Van Bortel
authors.forename: L
authors.initials: L
authors.lastname: Annemans
authors.forename: J P
authors.initials: JP
authors.lastname: Remon
authors.forename: I
authors.initials: I
authors.lastname: Van Tongelen
authors.forename: E
authors.initials: E
authors.lastname: Van Ganse
authors.forename: L
authors.initials: L
authors.lastname: Laforest
authors.forename: G
authors.initials: G
authors.lastname: Chamba
authors.forename: G
authors.initials: G
authors.lastname: Brusselle
mesh_terms: D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001530:Belgium; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D010349:Patient Compliance; D010366:Peak Expiratory Flow Rate; D012129:Respiratory Function Tests; D012189:Retrospective Studies
chemical_list: D018927:Anti-Asthmatic Agents